Clinical effect of non-convulsive electroconvulsive therapy combined with olanzapinedrug therapy in patients with schizophrenia

Kecai Tao^1*Qian Xiong²

• ¹Mental Health Center of Sichuan University Hospital, Chengdu, China
• ²West China Hospital of Sichuan University, Chengdu, China

Objective: To explore the clinical effect of non-convulsive electroconvulsive therapy combined with olanzapine drug therapy in schizophrenia patients. Methods: From September 2021 to August 2023, a total of 112 patients with schizophrenia treated in our hospital were selected as the study participants. These patients were randomly divided into a control group and a research group, with 56 cases in each group. Patients in the control group were administered olanzapine tablets. Based on olanzapine tablets, patients in the research group received non-convulsive electroconvulsive therapy. One hundred and twelve patients with schizophrenia received therapy in our hospital from September 2021 to August 2023 were chosen and randomly divided into control group (CG) and research group (RG). The CG was treated with olanzapine tablets. Based on the CG, patients in the RG were added with non-convulsive electroconvulsive therapy. The psychotic symptoms, severity of schizophrenia symptoms, memory ability, cognitive function, serum BDNF, S100B, and GFAP levels, and as well as incidence of adverse reactions in 2between the two groups were compared. Results: Compared to the control group, the research group had lower BPRS score, lower PANSS score, higher WMS-IV score, higher BACS score, higher serum BDNF level, lower serum S100B and GFAP levels (P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups After therapy, the BPRS score and PANSS scores in the RG presented decline as compared to the CG, while WMS-IV score and BACS score in the RG presented elevation as relative to the CG (P<0.05). After therapy, the serum BDNF level in the RG presented elevation as relative to the CG (P<0.05). Meanwhile, serum S100B and GFAP levels in the RG presented reduction as relative to the CG (P<0.05). The incidence of adverse reactions presented no difference between 2 groups (P>0.05). Conclusion: Non-convulsive electroconvulsive therapy combined with olanzapinedrug therapy has a significant effect in the therapy treatment of schizophrenia. It, which can effectively improve mental psychiatric symptoms and cognitive function of patients, regulate the levels of serum BDNF and S100Bserum BDNF and S100B levels, and is has high safety.